| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/26/2007 | US20070092933 Production of multimeric fusion proteins using a c4bp scaffold |
| 04/26/2007 | US20070092918 Detection of the PC-LECTIN protein which correlates to the presence of an androgen-dependent prostate cancer cell; drug target and diagnostic marker for prostate cancer |
| 04/26/2007 | US20070092912 Uses of human zven antagonists |
| 04/26/2007 | US20070092631 Composition and foods for lowering glycemic index |
| 04/26/2007 | US20070092584 comprising a thiazolidinedione, one or more of chromium picolinate or chromium polynicotinate; bioavailable source of vanadium is vanadyl sulfate; synergistic mixture |
| 04/26/2007 | US20070092575 Compositions for administering RNAIII-inhibiting peptides |
| 04/26/2007 | US20070092574 Controlled released compositions |
| 04/26/2007 | US20070092572 Bone cement compositions and the like comprising an RNAIII-inhibiting peptide |
| 04/26/2007 | US20070092540 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof |
| 04/26/2007 | US20070092533 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus |
| 04/26/2007 | US20070092529 Using gene encoding transmembrane ptorein |
| 04/26/2007 | US20070092527 Proton-sensing g-protein coupled receptors and dna sequences thereof |
| 04/26/2007 | US20070092519 Method for diagnosing chronic myeloid leukemia |
| 04/26/2007 | US20070092516 Antibody preparation |
| 04/26/2007 | US20070092513 Antiproliferative agents; anticancer agents; controlling excessive proliferation or migration of smooth muscle cells by treating said smooth muscle cells with an effective amount of an antagonist of a native ErbB4 receptor |
| 04/26/2007 | US20070092511 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| 04/26/2007 | US20070092504 Use of agents that modulate the interaction between PD-1 and its ligands in the downmodulation of immune responses |
| 04/26/2007 | US20070092503 Human alkaline sphingomyelinase and use thereof |
| 04/26/2007 | US20070092502 Method of Treating Glaucoma |
| 04/26/2007 | US20070092501 Compositions and methods relating to reduction of symptoms of autism |
| 04/26/2007 | US20070092499 Method for changing genetic properties of eukaryotic organism |
| 04/26/2007 | US20070092488 Methods of treating idiopathic pulmonary fibrosis |
| 04/26/2007 | US20070092487 use of a closure means coated by an inert fluorinated material (TEFLON) for a container of a liquid pharmaceutical composition ready for injection and containing a protein as active ingredient (interferon); human (HSA) serum albumins free |
| 04/26/2007 | US20070092486 Glycolated and glycosylated poultry derived therapeutic proteins |
| 04/26/2007 | US20070092485 Cytokine zalpha11 ligand |
| 04/26/2007 | US20070092484 MCP-1 splice variants and methods of using same |
| 04/26/2007 | US20070092482 Conjugates of a G-CSF moiety and a polymer |
| 04/26/2007 | US20070092472 solution for topical application to the skin consists of solutes and a solvent, where the solutes include ascorbate, tropocollagen factors, copper, and zinc gluconate; tropocollagen factors include L-proline, glycine and L-lysine; formulated to provide accelerated production of collagen proteins |
| 04/26/2007 | US20070092471 Composition for the oxidative treatment of hair or skin fixative compostion and method for permanent deformation of hair |
| 04/26/2007 | US20070092466 in combination with carrier, and optionally activity enhancer; arresting or reversing hair loss, or both, and promoting hair growth; also a mascara; thickening and darkening hair |
| 04/26/2007 | US20070092452 Human growth hormone (hGH); improved bioavailability |
| 04/26/2007 | US20070092444 Inhibition of inward sodium currents in cancer |
| 04/26/2007 | DE4332436B4 Cyclosporin enthaltende pharmazeutische Zusammensetzungen The cyclosporin-containing pharmaceutical compositions |
| 04/26/2007 | DE102005049637A1 Antagonisten gegen die Interaktion von PF4 und RANTES Antagonists to the interaction of PF4 and RANTES |
| 04/26/2007 | CA2626785A1 Use of prolactin in the prophylactic treatment of cancer |
| 04/26/2007 | CA2626692A1 Treatment of hypersensitivity |
| 04/26/2007 | CA2626518A1 Improved reproductive management |
| 04/26/2007 | CA2626456A1 Mtor pathway theranostic |
| 04/26/2007 | CA2626414A1 A composition comprising a coupled enzyme system |
| 04/26/2007 | CA2626361A1 Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions |
| 04/26/2007 | CA2626357A1 Intranasal administration of rapid acting insulin |
| 04/26/2007 | CA2626356A1 Modified proteases that inhibit complement activation |
| 04/26/2007 | CA2626238A1 Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| 04/26/2007 | CA2626206A1 Therapeutic agent for dentin-dental pulp complex regeneration |
| 04/26/2007 | CA2625888A1 Method of treating acute failure with thrombomodulin variant |
| 04/26/2007 | CA2625700A1 Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| 04/26/2007 | CA2625600A1 Natriuretic peptide modified transferrin fusion proteins |
| 04/26/2007 | CA2624763A1 Il-17c antagonists and methods of using the same |
| 04/26/2007 | CA2624648A1 Methods of decreasing vascular calcification using il-1 inhibitors |
| 04/26/2007 | CA2622397A1 Platelet aggregation inhibitor and health food effective in inhibiting platelet aggregation |
| 04/26/2007 | CA2622210A1 Glycolated and glycosylated poultry derived therapeutic proteins |
| 04/26/2007 | CA2592065A1 Glp-1 agonists, compositions, methods and uses |
| 04/25/2007 | EP1777519A1 Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| 04/25/2007 | EP1777234A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 |
| 04/25/2007 | EP1777233A2 Gonococcal proteins and nucleic acids |
| 04/25/2007 | EP1777231A2 Process of purication of LH and recominant hLH purified by that method |
| 04/25/2007 | EP1776964A1 Method of preventing and treating brain infarction |
| 04/25/2007 | EP1776960A1 Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions. |
| 04/25/2007 | EP1776959A2 Use of HGF for the manufacture of a medicament for treating fibrotic disorders |
| 04/25/2007 | EP1776958A2 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 04/25/2007 | EP1776957A2 Use of herpes vectors for tumor therapy |
| 04/25/2007 | EP1776954A2 The use of inhibitors of the renin-angiotensin system for the treatment of stroke |
| 04/25/2007 | EP1776459A1 Rage fusion proteins and methods of use |
| 04/25/2007 | EP1776456A2 Isolated chimeric proteins of modified lumazine synthase |
| 04/25/2007 | EP1776140A2 Methods of inhibiting viral replication |
| 04/25/2007 | EP1776139A2 Targeting damaged lung tissue |
| 04/25/2007 | EP1776138A1 tRNA SYNTHETASE FRAGMENTS |
| 04/25/2007 | EP1776137A1 Pharmaceutical composition containing botulinum neurotoxin a2 |
| 04/25/2007 | EP1776136A2 Treatment of conditions involving demyelination |
| 04/25/2007 | EP1776135A1 Ejection liquid, ejection device, ejection cartridge, and method of making droplets from liquid |
| 04/25/2007 | EP1776134A2 C-met kinase binding proteins |
| 04/25/2007 | EP1776133A1 Peptidic vasopressin receptor agonists |
| 04/25/2007 | EP1776132A2 Natriuretic compounds, conjugates, and uses thereof |
| 04/25/2007 | EP1776131A1 Methods for treating premature infants |
| 04/25/2007 | EP1776130A2 Pin1-modulating compounds and methods of use thereof |
| 04/25/2007 | EP1776128A1 Compositions for topical treatment |
| 04/25/2007 | EP1776099A1 Methods for improving bioavailability of a renin inhibitor |
| 04/25/2007 | EP1615652B1 Treatment of severe acute respiratory syndrome (sars) |
| 04/25/2007 | EP1526867B1 Erythropoietin in subpolycythemic doses |
| 04/25/2007 | EP1490401B1 Vegf peptides and their use |
| 04/25/2007 | EP1430133B1 A soluble toll-like receptor |
| 04/25/2007 | EP1337267B1 Use of blood coagulation factor xiii for treating haemophilia a |
| 04/25/2007 | EP1292326B1 Use of inactive cln2 proenzyme for treating lincl |
| 04/25/2007 | EP1259813B1 Diagnosis of malignant neoplasms |
| 04/25/2007 | EP1255554B1 Kidney-specific tumor vaccine directed against kidney tumor antigen g-250 |
| 04/25/2007 | EP1254174B1 Human cyr61 |
| 04/25/2007 | EP1223964B1 April receptor (bcma) and uses thereof |
| 04/25/2007 | EP1210948B1 Therapeutc peptide for nervous diseases |
| 04/25/2007 | EP1210425B1 Baff receptor (bcma), an immunoregulatory agent |
| 04/25/2007 | EP1190056B1 Human cytokine receptor |
| 04/25/2007 | EP1137465B1 Method for purification of a blood component |
| 04/25/2007 | EP1033134B1 Compositions inhibiting smooth muscle proliferation and method for the diagnosis of arteriosclerosis |
| 04/25/2007 | EP0984023B1 Cell surface molecule mediating cell adhesion and signal transmission |
| 04/25/2007 | EP0964925B1 A basal cell carcinoma tumor suppressor gene |
| 04/25/2007 | EP0960887B1 T cell epitope peptides |
| 04/25/2007 | EP0925358B1 Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use |
| 04/25/2007 | EP0901526B1 Cortistatin: neuropeptides, compositions and methods |
| 04/25/2007 | EP0804468B1 Method of making an omega-functionalized amino acid derivative |
| 04/25/2007 | CN2892127Y Respiratory tract disease therapeutic apparatus |
| 04/25/2007 | CN1954217A A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an HIV virus in an individual |